CN101412752A - 齐考诺肽的固相合成方法 - Google Patents
齐考诺肽的固相合成方法 Download PDFInfo
- Publication number
- CN101412752A CN101412752A CNA2007103015988A CN200710301598A CN101412752A CN 101412752 A CN101412752 A CN 101412752A CN A2007103015988 A CNA2007103015988 A CN A2007103015988A CN 200710301598 A CN200710301598 A CN 200710301598A CN 101412752 A CN101412752 A CN 101412752A
- Authority
- CN
- China
- Prior art keywords
- fmoc
- cys
- ziconotide
- resin
- solid phase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- BPKIMPVREBSLAJ-QTBYCLKRSA-N ziconotide Chemical compound C([C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]2C(=O)N[C@@H]3C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CSSC2)C(N)=O)=O)CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CSSC3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(N1)=O)CCSC)[C@@H](C)O)C1=CC=C(O)C=C1 BPKIMPVREBSLAJ-QTBYCLKRSA-N 0.000 title claims abstract description 42
- 229960002811 ziconotide Drugs 0.000 title claims abstract description 42
- 238000000034 method Methods 0.000 title claims abstract description 28
- 238000010532 solid phase synthesis reaction Methods 0.000 title claims abstract description 17
- 239000011347 resin Substances 0.000 claims abstract description 48
- 229920005989 resin Polymers 0.000 claims abstract description 48
- 125000006239 protecting group Chemical group 0.000 claims abstract description 26
- 150000001413 amino acids Chemical class 0.000 claims abstract description 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 14
- 238000007363 ring formation reaction Methods 0.000 claims abstract description 13
- 239000007790 solid phase Substances 0.000 claims abstract description 5
- 238000006482 condensation reaction Methods 0.000 claims abstract description 3
- 238000000746 purification Methods 0.000 claims abstract description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 59
- 238000006243 chemical reaction Methods 0.000 claims description 34
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 30
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 21
- 102000001189 Cyclic Peptides Human genes 0.000 claims description 17
- 108010069514 Cyclic Peptides Proteins 0.000 claims description 17
- UMRUUWFGLGNQLI-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-6-[(2-methylpropan-2-yl)oxycarbonylamino]hexanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCCNC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 UMRUUWFGLGNQLI-QFIPXVFZSA-N 0.000 claims description 12
- NDKDFTQNXLHCGO-UHFFFAOYSA-N 2-(9h-fluoren-9-ylmethoxycarbonylamino)acetic acid Chemical compound C1=CC=C2C(COC(=O)NCC(=O)O)C3=CC=CC=C3C2=C1 NDKDFTQNXLHCGO-UHFFFAOYSA-N 0.000 claims description 12
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 11
- 238000003756 stirring Methods 0.000 claims description 10
- REITVGIIZHFVGU-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[(2-methylpropan-2-yl)oxy]propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](COC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 REITVGIIZHFVGU-IBGZPJMESA-N 0.000 claims description 9
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 claims description 9
- 238000005406 washing Methods 0.000 claims description 9
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims description 7
- -1 protecting group amino acid Chemical class 0.000 claims description 7
- KLBPUVPNPAJWHZ-UMSFTDKQSA-N (2r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-tritylsulfanylpropanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)SC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 KLBPUVPNPAJWHZ-UMSFTDKQSA-N 0.000 claims description 6
- CSMYOORPUGPKAP-IBGZPJMESA-N (2r)-3-(acetamidomethylsulfanyl)-2-(9h-fluoren-9-ylmethoxycarbonylamino)propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CSCNC(=O)C)C(O)=O)C3=CC=CC=C3C2=C1 CSMYOORPUGPKAP-IBGZPJMESA-N 0.000 claims description 6
- OQYBTXFHTQYWCZ-UHFFFAOYSA-N 2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[(4-methylphenyl)methylsulfanyl]propanoic acid Chemical compound C1=CC(C)=CC=C1CSCC(C(O)=O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 OQYBTXFHTQYWCZ-UHFFFAOYSA-N 0.000 claims description 6
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 6
- 229910052740 iodine Inorganic materials 0.000 claims description 6
- 239000011630 iodine Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 5
- 150000003053 piperidines Chemical class 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- HNICLNKVURBTKV-NDEPHWFRSA-N (2s)-5-[[amino-[(2,2,4,6,7-pentamethyl-3h-1-benzofuran-5-yl)sulfonylamino]methylidene]amino]-2-(9h-fluoren-9-ylmethoxycarbonylamino)pentanoic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)N[C@H](C(O)=O)CCCN=C(N)NS(=O)(=O)C1=C(C)C(C)=C2OC(C)(C)CC2=C1C HNICLNKVURBTKV-NDEPHWFRSA-N 0.000 claims description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
- JAUKCFULLJFBFN-VWLOTQADSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[4-[(2-methylpropan-2-yl)oxy]phenyl]propanoic acid Chemical compound C1=CC(OC(C)(C)C)=CC=C1C[C@@H](C(O)=O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 JAUKCFULLJFBFN-VWLOTQADSA-N 0.000 claims description 3
- FODJWPHPWBKDON-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-[(2-methylpropan-2-yl)oxy]-4-oxobutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 FODJWPHPWBKDON-IBGZPJMESA-N 0.000 claims description 3
- CBPJQFCAFFNICX-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-methylpentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(C)C)C(O)=O)C3=CC=CC=C3C2=C1 CBPJQFCAFFNICX-IBGZPJMESA-N 0.000 claims description 3
- BUBGAUHBELNDEW-SFHVURJKSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-methylsulfanylbutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCSC)C(O)=O)C3=CC=CC=C3C2=C1 BUBGAUHBELNDEW-SFHVURJKSA-N 0.000 claims description 3
- QWXZOFZKSQXPDC-NSHDSACASA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](C)C(O)=O)C3=CC=CC=C3C2=C1 QWXZOFZKSQXPDC-NSHDSACASA-N 0.000 claims description 3
- LZOLWEQBVPVDPR-VLIAUNLRSA-N (2s,3r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[(2-methylpropan-2-yl)oxy]butanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H]([C@H](OC(C)(C)C)C)C(O)=O)C3=CC=CC=C3C2=C1 LZOLWEQBVPVDPR-VLIAUNLRSA-N 0.000 claims description 3
- VYMPLPIFKRHAAC-UHFFFAOYSA-N 1,2-ethanedithiol Chemical compound SCCS VYMPLPIFKRHAAC-UHFFFAOYSA-N 0.000 claims description 3
- 150000001408 amides Chemical class 0.000 claims description 3
- 239000012141 concentrate Substances 0.000 claims description 3
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 claims description 3
- 238000010511 deprotection reaction Methods 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 238000004366 reverse phase liquid chromatography Methods 0.000 claims description 2
- 125000001544 thienyl group Chemical group 0.000 claims description 2
- 239000000047 product Substances 0.000 abstract description 6
- 239000006227 byproduct Substances 0.000 abstract description 2
- 125000000415 L-cysteinyl group Chemical group O=C([*])[C@@](N([H])[H])([H])C([H])([H])S[H] 0.000 abstract 4
- 125000002228 disulfide group Chemical group 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 15
- 235000001014 amino acid Nutrition 0.000 description 12
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical group SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 238000001035 drying Methods 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- HBEDSQVIWPRPAY-UHFFFAOYSA-N 2,3-dihydrobenzofuran Chemical compound C1=CC=C2OCCC2=C1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- 241000237971 Conus magus Species 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 208000004404 Intractable Pain Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000004983 Phantom Limb Diseases 0.000 description 1
- 206010056238 Phantom pain Diseases 0.000 description 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000010719 annulation reaction Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 125000005519 fluorenylmethyloxycarbonyl group Chemical group 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000026781 habituation Effects 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000000063 presynaptic terminal Anatomy 0.000 description 1
- 238000004886 process control Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 125000002653 sulfanylmethyl group Chemical group [H]SC([H])([H])[*] 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Abstract
Description
序列 | 氨基酸名称 | 用量(克) |
1 | Fmoc-Cys(Mob)-OH | 57.9 |
2 | Fmoc-Lys(Boc)-OH | 58.6 |
3 | Fmoc-Gly-OH | 37.2 |
4 | Fmoc-Ser(tBu)-OH | 47.9 |
5 | Fmoc-Arg(Pbf)-OH | 81.1 |
6 | Fmoc-Cys(Trt)-OH | 73.2 |
7 | Fmoc-Ser(tBu)-OH | 47.9 |
8 | Fmoc-Gly-OH | 37.1 |
9 | Fmoc-Thr(tBu)-OH | 49.7 |
10 | Fmoc-Cys(Acm)-OH | 51.8 |
11 | Fmoc-Cys(Mob)-OH | 57.9 |
12 | Fmoc-Asp(OtBu)-OH | 51.4 |
13 | Fmoc-Tyr(tBu)-OH | 57.4 |
14 | Fmoc-Met-OH | 46.4 |
15 | Fmoc-Leu-OH | 44.1 |
16 | Fmoc-Arg(Pbf)-OH | 81.0 |
17 | Fmoc-Ser(tBu)-OH | 47.9 |
18 | Fmoc-Cys(Trt)-OH | 73.2 |
19 | Fmoc-Lys(Boc)-OH | 58.5 |
20 | Fmoc-Ala-OH | 38.9 |
21 | Fmoc-Gly-OH | 37.1 |
22 | Fmoc-Lys(Boc)-OH | 58.5 |
23 | Fmoc-Gly-OH | 37.1 |
24 | Fmoc-Lys(Boc)-OH | 58.5 |
25 | Fmoc-Cys(Acm)-OH | 51.8 |
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007103015988A CN101412752B (zh) | 2007-12-26 | 2007-12-26 | 齐考诺肽的固相合成方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2007103015988A CN101412752B (zh) | 2007-12-26 | 2007-12-26 | 齐考诺肽的固相合成方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101412752A true CN101412752A (zh) | 2009-04-22 |
CN101412752B CN101412752B (zh) | 2011-12-07 |
Family
ID=40593514
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2007103015988A Expired - Fee Related CN101412752B (zh) | 2007-12-26 | 2007-12-26 | 齐考诺肽的固相合成方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101412752B (zh) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102268082A (zh) * | 2011-05-27 | 2011-12-07 | 江苏江神药物化学有限公司 | 一种齐考诺肽的固相合成方法 |
CN103214550A (zh) * | 2013-03-14 | 2013-07-24 | 苏州强耀生物科技有限公司 | 多对二硫键定点环化固相合成多肽新工艺 |
CN103242441A (zh) * | 2013-05-27 | 2013-08-14 | 江苏施美康药业股份有限公司 | 一种齐考诺肽的固相合成方法 |
CN103626849A (zh) * | 2013-11-27 | 2014-03-12 | 深圳翰宇药业股份有限公司 | 一种利那洛肽的制备方法 |
CN103819551A (zh) * | 2014-03-18 | 2014-05-28 | 中国人民解放军第四军医大学 | Orexin多肽的化学制备方法及用途 |
CN103884808A (zh) * | 2012-12-21 | 2014-06-25 | 深圳翰宇药业股份有限公司 | 一种齐考诺肽及其杂质的检测方法 |
CN103992389A (zh) * | 2013-09-10 | 2014-08-20 | 杭州诺泰制药技术有限公司 | 一种固环合成去氨加压素的方法 |
CN104211777A (zh) * | 2013-05-30 | 2014-12-17 | 深圳翰宇药业股份有限公司 | 一种皮卡那肽的制备方法 |
CN104974237A (zh) * | 2015-07-18 | 2015-10-14 | 济南康和医药科技有限公司 | 一种片段法固相合成齐考诺肽的方法 |
CN106243194A (zh) * | 2016-09-12 | 2016-12-21 | 兰州凯博药业股份有限公司 | 一种改进的Fmoc多肽固相合成缩宫素的方法 |
CN106554391A (zh) * | 2015-09-29 | 2017-04-05 | 深圳翰宇药业股份有限公司 | 一种海洋生物肽Xen2174的合成方法 |
CN106967155A (zh) * | 2017-03-17 | 2017-07-21 | 兰州凯博药业股份有限公司 | 一种多肽液相合成缩宫素的方法 |
CN107098952A (zh) * | 2017-05-03 | 2017-08-29 | 安徽工程大学 | 抗菌环(甘氨酸‑色氨酸‑亮氨酸‑d‑亮氨酸‑缬氨酸‑天冬酰胺)肽的制备方法 |
CN107216374A (zh) * | 2017-05-26 | 2017-09-29 | 重庆莱美隆宇药业有限公司 | 一种齐考诺肽的合成方法 |
CN108047324A (zh) * | 2018-02-01 | 2018-05-18 | 润辉生物技术(威海)有限公司 | 一种ω-芋螺毒素GVIA的制备方法 |
CN108059663A (zh) * | 2018-02-10 | 2018-05-22 | 润辉生物技术(威海)有限公司 | 一种来考诺肽的制备方法 |
CN108409831A (zh) * | 2018-03-05 | 2018-08-17 | 苏州强耀生物科技有限公司 | 一种固相定点氧化二硫键合成iRGD多肽的方法 |
CN115806607A (zh) * | 2022-12-27 | 2023-03-17 | 哈尔滨吉象隆生物技术有限公司 | 一种氯毒素多肽的定点环化方法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106496315A (zh) * | 2016-10-24 | 2017-03-15 | 合肥国肽生物科技有限公司 | 一种高效的齐考诺肽合成制备方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004080444A2 (en) * | 2003-03-10 | 2004-09-23 | Dynogen Pharmaceuticals, Inc. | Methods for treating lower urinary tract disorders and the related disorders vulvodynia and vulvar vestibulitis using cav2.2 subunit calcium channel modulators |
CN1232535C (zh) * | 2003-07-30 | 2005-12-21 | 浙江大学 | 芋螺毒素mvii a基因的gst融合表达及其应用 |
WO2005032556A1 (en) * | 2003-10-02 | 2005-04-14 | Elan Pharmaceuticals, Inc. | Method for reducing pain |
CN1304422C (zh) * | 2005-09-15 | 2007-03-14 | 浙江大学 | 非酰胺化ω-芋螺毒素M ⅦA 及其制备方法和应用 |
-
2007
- 2007-12-26 CN CN2007103015988A patent/CN101412752B/zh not_active Expired - Fee Related
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102268082B (zh) * | 2011-05-27 | 2013-04-17 | 江苏江神药物化学有限公司 | 一种齐考诺肽的固相合成方法 |
CN102268082A (zh) * | 2011-05-27 | 2011-12-07 | 江苏江神药物化学有限公司 | 一种齐考诺肽的固相合成方法 |
CN103884808B (zh) * | 2012-12-21 | 2016-03-30 | 深圳翰宇药业股份有限公司 | 一种齐考诺肽及其杂质的检测方法 |
CN103884808A (zh) * | 2012-12-21 | 2014-06-25 | 深圳翰宇药业股份有限公司 | 一种齐考诺肽及其杂质的检测方法 |
CN103214550A (zh) * | 2013-03-14 | 2013-07-24 | 苏州强耀生物科技有限公司 | 多对二硫键定点环化固相合成多肽新工艺 |
CN103242441A (zh) * | 2013-05-27 | 2013-08-14 | 江苏施美康药业股份有限公司 | 一种齐考诺肽的固相合成方法 |
CN104211777A (zh) * | 2013-05-30 | 2014-12-17 | 深圳翰宇药业股份有限公司 | 一种皮卡那肽的制备方法 |
CN103992389B (zh) * | 2013-09-10 | 2018-04-06 | 杭州阿诺生物医药科技股份有限公司 | 一种固环合成去氨加压素的方法 |
CN103992389A (zh) * | 2013-09-10 | 2014-08-20 | 杭州诺泰制药技术有限公司 | 一种固环合成去氨加压素的方法 |
CN103626849B (zh) * | 2013-11-27 | 2017-01-11 | 深圳翰宇药业股份有限公司 | 一种利那洛肽的制备方法 |
CN103626849A (zh) * | 2013-11-27 | 2014-03-12 | 深圳翰宇药业股份有限公司 | 一种利那洛肽的制备方法 |
CN103819551A (zh) * | 2014-03-18 | 2014-05-28 | 中国人民解放军第四军医大学 | Orexin多肽的化学制备方法及用途 |
CN103819551B (zh) * | 2014-03-18 | 2017-01-04 | 中国人民解放军第四军医大学 | Orexin多肽的化学制备方法及用途 |
CN104974237A (zh) * | 2015-07-18 | 2015-10-14 | 济南康和医药科技有限公司 | 一种片段法固相合成齐考诺肽的方法 |
CN104974237B (zh) * | 2015-07-18 | 2019-02-12 | 济南康和医药科技有限公司 | 一种片段法固相合成齐考诺肽的方法 |
CN106554391A (zh) * | 2015-09-29 | 2017-04-05 | 深圳翰宇药业股份有限公司 | 一种海洋生物肽Xen2174的合成方法 |
CN106243194A (zh) * | 2016-09-12 | 2016-12-21 | 兰州凯博药业股份有限公司 | 一种改进的Fmoc多肽固相合成缩宫素的方法 |
WO2018166146A1 (zh) * | 2017-03-17 | 2018-09-20 | 兰州凯博药业股份有限公司 | 一种多肽液相合成缩宫素的方法 |
CN106967155A (zh) * | 2017-03-17 | 2017-07-21 | 兰州凯博药业股份有限公司 | 一种多肽液相合成缩宫素的方法 |
CN106967155B (zh) * | 2017-03-17 | 2018-05-15 | 兰州凯博药业股份有限公司 | 一种多肽液相合成缩宫素的方法 |
CN107098952A (zh) * | 2017-05-03 | 2017-08-29 | 安徽工程大学 | 抗菌环(甘氨酸‑色氨酸‑亮氨酸‑d‑亮氨酸‑缬氨酸‑天冬酰胺)肽的制备方法 |
CN107216374A (zh) * | 2017-05-26 | 2017-09-29 | 重庆莱美隆宇药业有限公司 | 一种齐考诺肽的合成方法 |
CN108047324A (zh) * | 2018-02-01 | 2018-05-18 | 润辉生物技术(威海)有限公司 | 一种ω-芋螺毒素GVIA的制备方法 |
CN108059663A (zh) * | 2018-02-10 | 2018-05-22 | 润辉生物技术(威海)有限公司 | 一种来考诺肽的制备方法 |
CN108409831A (zh) * | 2018-03-05 | 2018-08-17 | 苏州强耀生物科技有限公司 | 一种固相定点氧化二硫键合成iRGD多肽的方法 |
CN115806607A (zh) * | 2022-12-27 | 2023-03-17 | 哈尔滨吉象隆生物技术有限公司 | 一种氯毒素多肽的定点环化方法 |
Also Published As
Publication number | Publication date |
---|---|
CN101412752B (zh) | 2011-12-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101412752B (zh) | 齐考诺肽的固相合成方法 | |
CN105017387B (zh) | 一种制备利那洛肽的方法 | |
CN101463072B (zh) | 一种八肽胆囊收缩素的制备方法 | |
CN109456402A (zh) | 一种索玛鲁肽的合成方法 | |
CN106167514A (zh) | 一种利那洛肽的合成和纯化方法 | |
CN101407540A (zh) | 一种亮丙瑞林的固相合成方法 | |
CN101696236B (zh) | 一种固相合成阿托西班方法 | |
CN107501408A (zh) | 一种特立帕肽的制备方法 | |
CN101857629A (zh) | 布雷默浪丹的固相合成方法 | |
CN1923849B (zh) | 固相多肽合成奥曲肽的制备方法 | |
CN107056894B (zh) | 一种片段法固相合成醋酸加尼瑞克的方法 | |
CN106478805A (zh) | 一种glp-1衍生物的制备方法 | |
CN108059667B (zh) | 一种兰瑞肽的固相合成方法 | |
CN102286078A (zh) | 一种多肽hm-3的制备方法 | |
CN111748019A (zh) | 一种多肽衍生化合物的合成方法 | |
CN109053863A (zh) | 一种低成本制备高纯度利那洛肽的方法 | |
CN105111301B (zh) | 一种鲑鱼降钙素的制备方法 | |
CN103351426B (zh) | 一种醋酸奥曲肽的多肽合成方法 | |
CN104311640B (zh) | 一种免疫修复15肽、其制备方法及其应用 | |
CN1865282B (zh) | 固相多肽合成特利加压素的制备方法 | |
CN104497130A (zh) | 一种兰瑞肽的制备方法 | |
CN106397542A (zh) | 特异性微波合成制备醋酸曲普瑞林的方法 | |
CN105367627A (zh) | 一种特利加压素的制备方法 | |
CN112175066B (zh) | 一种制备舍莫瑞林的方法 | |
CN104277097A (zh) | 固相片段法制备猪o型口蹄疫合成肽抗原2700的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: HANGZHOU ADELAI NUOTAI PHARMACEUTICAL TECHNOLOGY C Free format text: FORMER NAME: HANGZHOU SINOPEP PHARMACEUTICAL INC. |
|
CP01 | Change in the name or title of a patent holder |
Address after: Hangzhou City, Zhejiang province 310018 Hangzhou economic and Technological Development Zone No. 6 Street No. 452 Hangzhou City high-tech incubator incubator building No. 1 room 3B01-3B04 Patentee after: HANGZHOU ADLAI NORTYE PHARMACEUTICAL TECHNOLOGY CO., LTD. Address before: Hangzhou City, Zhejiang province 310018 Hangzhou economic and Technological Development Zone No. 6 Street No. 452 Hangzhou City high-tech incubator incubator building No. 1 room 3B01-3B04 Patentee before: Hangzhou Sinopep Pharmaceutical Inc. |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Solid-phase synthesis method of Ziconotide Effective date of registration: 20150116 Granted publication date: 20111207 Pledgee: Bank of Hangzhou Limited by Share Ltd Binjiang branch Pledgor: HANGZHOU ADLAI NORTYE PHARMACEUTICAL TECHNOLOGY CO., LTD. Registration number: 2015990000044 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
C56 | Change in the name or address of the patentee | ||
CP01 | Change in the name or title of a patent holder |
Address after: Hangzhou City, Zhejiang province 310018 Hangzhou economic and Technological Development Zone No. 6 Street No. 452 Hangzhou City high-tech incubator incubator building No. 1 room 3B01-3B04 Patentee after: HANGZHOU ANUO BIOLOGICAL MEDICINE TECHNOLOGY CO., LTD. Address before: Hangzhou City, Zhejiang province 310018 Hangzhou economic and Technological Development Zone No. 6 Street No. 452 Hangzhou City high-tech incubator incubator building No. 1 room 3B01-3B04 Patentee before: HANGZHOU ADLAI NORTYE PHARMACEUTICAL TECHNOLOGY CO., LTD. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20111207 Termination date: 20191226 |